XASX
TRJ
Market cap69mUSD
Jun 11, Last price
0.70AUD
1D
-3.45%
1Q
-22.22%
IPO
-66.02%
Name
Trajan Group Holdings Ltd
Chart & Performance
P/E
—
P/S
0.69
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.30%
Rev. gr., 5y
18.00%
Revenues
155m
-4.40%
Net income
-25m
L
CFO
9m
-0.80%
Profile
Trajan Group Holdings Limited develops, manufactures, sells, and distributes analytical and life science products and devices in Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India. The company operates through two segments, Analytical Products and Life Science Solutions. It offers analytical products, including syringes, GC consumables, septas, caps, liners, gas filters, and tubing products; pathology solutions; and sampling products, as well as automation systems for the analysis of biological, food, and environmental samples. The company also provides nutrition testing solutions for pathology laboratories, research and clinical trials, personalized nutrition, corporate wellness, and health insurance. In addition, it offers automation workflow solutions, micro sampling devices, and data analysis services. Trajan Group Holdings Limited was incorporated in 2011 and is headquartered in Ringwood, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||
Revenues | 155,023 -4.40% | 162,154 50.74% | 107,574 40.49% | |||||
Cost of revenue | 189,917 | 186,923 | 97,452 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (34,894) | (24,769) | 10,122 | |||||
NOPBT Margin | 9.41% | |||||||
Operating Taxes | (5,779) | 3,586 | 546 | |||||
Tax Rate | 5.39% | |||||||
NOPAT | (29,115) | (28,355) | 9,576 | |||||
Net income | (25,329) -1,440.87% | 1,889 10.86% | 1,704 -9.36% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 4,346 | 29,114 | ||||||
BB yield | -1.57% | -10.71% | ||||||
| Debt | ||||||||
Debt current | 45,975 | 11,762 | 56,380 | |||||
Long-term debt | 22,249 | 60,380 | 21,138 | |||||
Deferred revenue | 10,837 | (7,093) | ||||||
Other long-term liabilities | 387 | 549 | 324 | |||||
Net debt | 56,844 | 59,554 | 62,894 | |||||
| Cash flow | ||||||||
Cash from operating activities | 9,475 | 9,551 | 2,134 | |||||
CAPEX | (3,040) | (8,553) | (3,415) | |||||
Cash from investing activities | (3,040) | (8,553) | (116,382) | |||||
Cash from financing activities | (6,400) | (3,364) | 74,689 | |||||
FCF | (19,071) | (43,989) | (20,023) | |||||
| Balance | ||||||||
Cash | 11,243 | 11,038 | 13,164 | |||||
Long term investments | 137 | 1,550 | 1,460 | |||||
Excess cash | 3,629 | 4,480 | 9,245 | |||||
Stockholders' equity | 102,849 | 129,529 | 116,506 | |||||
Invested Capital | 155,770 | 186,903 | 166,460 | |||||
ROIC | 9.58% | |||||||
ROCE | 5.54% | |||||||
| EV | ||||||||
Common stock shares outstanding | 152,201 | 153,295 | 135,861 | |||||
Price | 1.02 -43.65% | 1.81 -9.50% | 2.00 -12.66% | |||||
Market cap | 155,245 -44.05% | 277,464 2.11% | 271,721 -8.31% | |||||
EV | 212,089 | 337,018 | 334,615 | |||||
EBITDA | (34,894) | (19,407) | 12,348 | |||||
EV/EBITDA | 27.10 | |||||||
Interest | 4,536 | 4,024 | 663 | |||||
Interest/NOPBT | 6.55% | |||||||